Chardan Capital Has Strong Estimate for MCRB FY2025 Earnings

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Chardan Capital raised their FY2025 earnings estimates for shares of Seres Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will earn ($0.57) per share for the year, up from their prior estimate of ($0.73). Chardan Capital currently has a “Buy” rating and a $1.25 price objective on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($0.38) per share.

MCRB has been the topic of a number of other reports. StockNews.com upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. The Goldman Sachs Group decreased their price target on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a research note on Friday, March 14th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.00.

Seres Therapeutics Trading Down 4.5 %

MCRB stock opened at $0.72 on Thursday. The company’s 50 day moving average is $0.78 and its two-hundred day moving average is $0.82. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $1.53. The stock has a market cap of $125.71 million, a P/E ratio of -3.13 and a beta of 2.19.

Institutional Trading of Seres Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its position in shares of Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 222,771 shares during the period. FMR LLC boosted its stake in Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares during the last quarter. Providence Wealth Advisors LLC grew its holdings in Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the period. State Street Corp increased its stake in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 43,700 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after acquiring an additional 255,014 shares during the period. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.